Skip to main content Skip to navigation

Anil Singh

Anil Singh
Assistant Professor, Pharmaceutical Sciences 509-368-6545 PBS 423 Spokane


2008 PhD (Biochemistry) Centre for DNA Fingerprinting and Diagnostics,

Hyderabad Central University, Hyderabad, India.

2001 MS (Biochemistry) Hamdard University, New Delhi, India.

1999 BS (Biotechnology) B N College, Patna University, Patna, India.

Additional training

2009-2013 The Ohio State University, Columbus, OH (Postdoctoral Researcher)

2008-2009 University of Maryland Baltimore, Baltimore, MD (Postdoctoral Researcher)


Anil Singh’s research focus is on understanding the mechanisms and therapeutic targeting of inflammation and autoimmunity. Currently, he is working towards

1) Understanding the influence of IL-6 trans-signaling on rheumatoid arthritis (RA) microenvironment and disease progression, and

2) Exploring novel therapeutic targets for RA and Gouty inflammation, in particular, the preclinical therapeutic targeting of MCSF/RANKL, IL-6, IL-1α, IL-1β and TNF signaling, and targeting post transcriptional stability of IL-1α and IL-1β through the ubiquitin proteasome system.

Additional Information

Anil Singh obtained his PhD in Biochemistry from the Department of Life Sciences, University of Hyderabad, India. He worked on elucidating the inflammatory role of human Resistin, a protein secreted by monocytes and macrophages, in diabetes and obesity at the Centre for DNA Fingerprinting and Diagnostics for his graduate thesis. He went on to gain postdoctoral training at the University of Maryland Baltimore and The Ohio State University before joining Washington State University in 2014. His postdoctoral research work focused on the role of Complement pathway in the pathogenesis of Multiple Sclerosis and the characterization of Ets2 and PTEN protein interactions through hybridization on a high density, 17000 full-length protein library. Anil has published several research papers as a primary author in high impact, peer-reviewed scientific journals like Arthritis & Rheumatology, Journal of Immunology, Cellular and Molecular Immunology and FASEB Journal. His notable work has led to the discovery of the drug target TGFβ-activated kinase 1 (TAK1) for the treatment of rheumatoid arthritis. He has also served as an editorial expert on three research papers specific to rheumatoid arthritis, and has conducted more than 100 peer reviews of manuscripts submitted to various international journals published by MDPI and Elsevier publishers, including Cancer, International Journal of Molecular Sciences, Molecules, Nutrients, Journal of Advance Research, Experimental and Molecular Pathology, and Toxicology and Applied Pharmacology.

Honors and Awards

Pelotonia Postdoctoral fellowship 2010-2012

Italian Government Research fellowship 2007

Best poster award, Indo-Australian symposia, 2006

UGC-CSIR-SRF fellowship, Govt. of India, 2003

UGC-CSIR-JRF fellowship, Govt. of India, 2001

ICMR-JRF fellowship, Govt. of India, 2001

Graduate Aptitude Test of Engineering, 2001


American College of Rheumatology, USA

American Association for the advancement of Science, USA

Peer-Reviewed Publications

  1. Singh AK, Haque M, Sullivan KO, Chourasia, Ouseph M, Ahmed S Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-β-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system Nature Cellular and Molecular Immunology DOI: 10.1038/s41423-019-0284-3
  2. Fechtner SC*,Singh AK*, Srivatsava I, Szlenk CT, Menench T, Natesan S, Ahmed S Cannabinoid receptor 2 agonist JWH-015 inhibits Interleukin-1β-induced inflammation in Rheumatoid arthritis synovial fibroblasts and in adjuvant induced arthritis rat via glucocorticoid receptor Frontiers Immunology DOI: 10.3389/fimmu.2019.01027 * Equal contribution
  3. Fechtner SC Singh AKAhmed S  Role of cannabinoid receptor 2 in mediating interleukin-1β-induced inflammation in rheumatoid arthritis synovial fibroblasts. Clinical and Experimental Rheumatology  [18 Mar 2019]
  4. Singh AK, Fechtner S, Chourasia M, Sicalo J, Ahmed S. Critical role of IL-1α in IL-1β–induced inflammatory responses: cooperation with NF-κBp65 in transcriptional regulation. FASEB J.2018 Oct 1:fj201801513R. doi: 10.1096/fj.201801513R.
  5. Kim EY, Sudini K, Singh AK, Haque M, Leaman D, Khuder S, Ahmed S. Ursolic acid facilitates apoptosis in rheumatoid arthritis synovial fibroblasts by inducing SP1-mediated Noxa expression and proteasomal degradation of Mcl-1. FASEB J. 2018 May 25; p.fj201800425R. doi:1096/fj.201800425R.
  6. Fechtner S, Singh AK, Chourasia M, Ahmed S. Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1β signaling in rheumatoid arthritis synovial fibroblasts. Toxicol Appl Pharmacol. 2017 May; 329:112-120.
  7. Umar S, Tyagi AM, Singh AK, Haseeb A. Molecular mechanism of rheumatic diseases and efficacy of current therapies. Biomed Res Int. 2017; 2017:2401329. (Editorial)
  8. Akhtar N, Singh AK, Ahmed S. MicroRNA-17 Suppresses TNF-α Signaling by interfering with TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts. J Immunol. 2016 Sep;197(6):2219-28.
  9. Singh AK, Umar S, Riegsecker S, Chourasia M, Ahmed S. Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6. Arthritis Rheumatology. 2016 Feb; 68(2):347-58. (Featured on cover page)
  10. Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. Toxicol Appl Pharmacology. 2015 Sep 15;287(3):299-305
  11. Tegla CA, Cudrici CD, Azimzadeh P, Singh AK, Trippe R 3rd, Khan A, Chen H, Andrian-Albescu M, Royal W 3rd, Bever C, Rus V, Rus H. Dual role of Response gene to complement-32 in multiple sclerosis. Exp Mol Pathol. 2013; 94 (1): 17-28.
  12. Tegla CA, Cudrici C, Rozycka M, Soloviova K, Ito T, Singh AK, Khan A, Azimzadeh P, Andrian-Albescu M, Khan A, Niculescu F, Rus V, Judge SI, Rus H. C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation. Exp Mol Pathol. 2011; 91(1): 335-45.
  13. Singh AK, Aruna B, Mohareer K, Hasnain SE, Ehtesham NZ. Transcription of Human Resistin Gene Involves an Interaction of Sp1 with Peroxisome Proliferator-Activating Receptor Gamma (PPARγ). PLoS One 2010; 5 (3): e9912.
  14. Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh AK, Rus H. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J. Neuroimmunol. 2009; 213 (1-2): 3-11. (Featured on cover page)
  15. Aruna B, Islam A, Ghosh S, Singh AK, Vijayalakshmi M, Ahmad F, Ehtesham NZ. Biophysical analyses of human resistin: oligomer formation suggests novel biological function. Biochemistry 2008; 47 (47): 12457-66.
  16. Silswal N*, Singh AK*, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem.  Biophys. Res. Commun. 2005; 334 (4): 1092-101. * Equal contribution.
  17. Aruna B, Ghosh S, Singh AK, Mande SC, Srinivas V, Chauhan R, Ehtesham NZ. Human recombinant resistin protein displays a tendency to aggregate by forming intermolecular disulphide linkages. Biochemistry 2003; 42 (36): 10554-9.
  18. Ghosh S, Singh AK, Aruna B, Mukhopadhyay S and Ehtesham NZ. The genomic organization of mouse resistin reveals major differences   from the human resistin: functional implications. Gene 2003; 305: 27-34.